Scarborough Advisors, LLC Cardiff Oncology, Inc. Transaction History
Scarborough Advisors, LLC
- $452 Million
- Q2 2025
A detailed history of Scarborough Advisors, LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Scarborough Advisors, LLC holds 7,502 shares of CRDF stock, worth $17,929. This represents 0.01% of its overall portfolio holdings.
Number of Shares
7,502Holding current value
$17,929% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CRDF
# of Institutions
122Shares Held
30.1MCall Options Held
900KPut Options Held
234K-
Commodore Capital LP New York, NY5.38MShares$12.9 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.73MShares$8.91 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$6.28 Million0.0% of portfolio
-
Blair William & CO Chicago, IL2.52MShares$6.03 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA1.5MShares$3.58 Million0.0% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $104M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...